Clinical trials: Empagliflozin
Heart Failure
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%.
- Trial name
- NCT06935370
- Testing
- vicadrostat, empagliflozin
- Where
- 594 sites in United States, Argentina and 27 more
- Volunteers
- 4,200 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once daily oral doses of empagliflozin in Japanese patients with type 1 diabetes mellitus as adjunctive therapy to insulin.
- Trial name
- NCT02702011
- Testing
- empagliflozin medium dose, empagliflozin low dose, empagliflozin high dose
- Where
- 4 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
SIADH
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
Syndrome of inappropriate antidiuresis (SIADH) is characterized by an imbalance of antidiuretic vasopressin (AVP) secretion. The impaired AVP regulation leads to water retention and secondary natriuresis and is a common cause for…
- Trial name
- SAND (NCT02874807)
- Testing
- Empagliflozin
- Where
- Switzerland
- Volunteers
- 88 people
- Sponsor
- University Hospital, Basel, Switzerland
Heart Failure
Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale
This study aims at exploring the use of Dapagliflozin and Empagliflozin in children and adolescents 6-18 years old with heart failure.
- Trial name
- NCT06012266
- Testing
- Dapagliflozin tablet, Empagliflozin Tablets
- Where
- 3 sites in Switzerland, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Diabetic Nephropathies
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
The MEDiaN study aims to examine the state of fuel metabolism in participants with diabetic nephropathy (DN) before and after the use of the sodium-glucose transport protein 2 inhibitor (SGLT-2i) empagliflozin.
- Trial name
- (MEDiaN) (NCT03933956)
- Testing
- Empagliflozin 10 MG
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Singapore General Hospital
NAFLD (Nonalcoholic Fatty Liver Disease)
A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.
The goal of this clinical trial is to learn if drugs Dapagliflozin and Empagliflozin work to treat NAFLD in Type 2 diabetes patients. It will also learn about the safety of drugs dapagliflozin and empagliflozin.
- Trial name
- (Dapa)& (Empa) (NCT07363707)
- Testing
- Dapagliflozin + Metformin, Empa
- Where
- Egypt
- Volunteers
- 108 people
- Sponsor
- Beni-Suef University
Diabetic Kidney Disease (DKD), Type 2 Diabetes
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
We are conducting this clinical trial to find out whether Guominkang-a traditional Chinese herbal formula-is safe and effective for people with diabetic kidney disease (DKD).
- Conditions
- Diabetic Kidney Disease (DKD), Type 2 Diabetes, Albuminuria
- Trial name
- NCT07907965
- Testing
- Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing University of Chinese Medicine
Healthy
Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets
The trial is being conducted to establish the bioequivalence of emp/met (12.5mg/500mg) fixed dose combination tablets compared to tablets administered together in healthy male and female volunteers under fed conditions.
- Trial name
- NCT02028767
- Testing
- Empagliflozin 2.5 mg, Empagliflozin 10 mg, Metformin 500 mg
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers
The objective of the study was to investigate whether there is a drug-drug interaction between BI 10773 and pioglitazone when co-administered as multiple oral doses.
- Trial name
- NCT02276365
- Testing
- BI 10773, Pioglitazone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents
The purpose of this study is to compare the incidence of diabetic ketoacidosis (DKA) among participants diagnosed with type 2 diabetes mellitus (T2DM) and pair-matched on exposure propensity scores for new use of any…
- Trial name
- NCT02636192
- Testing
- No Intervention
- Volunteers
- 200,000 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Kidney Disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.
- Trial name
- NCT07107945
- Testing
- Empagliflozin
- Where
- 93 sites in United States, Argentina and 16 more
- Volunteers
- 135 people
- Sponsor
- Boehringer Ingelheim
Mild Cognitive Impairment, Cognitive Impairment
SNIFF - Combo INI+EMPA Trial
The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2…
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05081219
- Testing
- Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Peripheral Arterial Disease(PAD)
Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
The study is observational and involves patients (pts) with peripheral arterial occlusive disease (PAD) who have undergone lower limb revascularization procedures.
- Trial name
- NCT07157475
- Testing
- Treatment with SGLT2 inhibitors (flozins)
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Wroclaw Medical University
Breast Cancer, Supportive Care in Cancer
EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)
The primary objective of this pilot study is to evaluate the feasibility and acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy.
- Trial name
- EMBRACE (NCT07883512)
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Non-Alcoholic Fatty Liver Disease, Type2diabetes
Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
This clinical trial will yield results about the therapeutic effect of combining pioglitazone with SGLT2i in people suffering from NAFLD associated with T2DM.
- Trial name
- NCT05942963
- Testing
- Empagliflozin 10 MG, Pioglitazone 15mg, Metformin
- Where
- Pakistan
- Volunteers
- 240 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Obesity, Pre-diabetes
SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue.
- Trial name
- NCT04907214
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt University Medical Center
Liver Diseases, Hypertension, Portal
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis caused by hepatitis B, hepatitis C or nonalcoholic steatohepatitis (NASH). People can join this study if they have high blood pressure in the portal vein (main vessel going to the…
- Trial name
- NCT05282121
- Testing
- Avenciguat, Empagliflozin
- Where
- 31 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)
The objective of this study was to compare the effectiveness of sodium glucose co-transporter 2 (SGLT2) inhibitors relative to metformin for reducing subsequent cardiovascular events in patients with type 2 diabetes mellitus.
- Trial name
- NCT03627039
- Testing
- SGLT2, Metformin
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus, Mild Cognitive Impairment
Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial
This is a prospective, randomized, open label, parallel, 16-week study to explore and evaluate the therapeutic effects of Henagliflozin on the cognitive function, olfactory function, and odor-induced brain activation in T2DM…
- Trial name
- NCT06085703
- Testing
- Henagliflozin, Gliclazide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
DMD-associated Dilated Cardiomyopathy
Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age
This study aims at exploring the use of empagliflozin in children and adolescents 6-18 years old with Duchenne muscular distrophy (DMD) - associated cardiomyopathy.
- Trial name
- REDMeD (NCT06643442)
- Testing
- Empagliflozin Tablets
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Sebastiano Lava